What are the markers of aggressiveness in prolactinomas? Changes in cell biology, extracellular matrix components, angiogenesis and genetics

European Journal of Endocrinology

Volumn 156, Issue 2, 2007, Pages 143-153

  Gürlek, Alper ^a,b   Karavitaki, Niki ^a   Ansorge, Olaf ^b   Wass, John A H ^a  

^a CHURCHILL HOSPITAL   (United Kingdom)

^b RADCLIFFE INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENINE; BROMOCRIPTINE; CABERGOLINE; CATENIN; CELL ADHESION MOLECULE; CYCLINE; DOPAMINE RECEPTOR STIMULATING AGENT; ESTROGEN; FIBROBLAST GROWTH FACTOR; GUANINE; HEPARIN BINDING SECRETORY TRANSFORMING PROTEIN; KI 67 ANTIGEN; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; NERVE CELL ADHESION MOLECULE; PERGOLIDE; PROLACTIN; PROTEIN EDPM5; QUINAGOLIDE; SECURIN; TUMOR MARKER; UNCLASSIFIED DRUG; UVOMORULIN; VASCULOTROPIN;

BRAIN METASTASIS; CANCER GENETICS; CANCER INVASION; CARCINOGENESIS; CARCINOMA; CELL ADHESION; CELL CYCLE REGULATION; CELL MIGRATION; CELL PROLIFERATION; DRUG HYPERSENSITIVITY; EXTRACELLULAR MATRIX; GENE LOSS; GENE MUTATION; GENE OVEREXPRESSION; GENETIC POLYMORPHISM; HUMAN; HYPOPHYSIS DISEASE; NEUROSURGERY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOGENE RAS; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROLACTINOMA; PROTEIN EXPRESSION; PROTEIN INDUCTION; REVIEW; SPINE METASTASIS; TUMOR GROWTH; TUMOR SUPPRESSOR GENE; TUMOR VASCULARIZATION; GENETICS; HYPOPHYSIS TUMOR; METABOLISM; NEOVASCULARIZATION (PATHOLOGY);

EXTRACELLULAR MATRIX; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; PITUITARY NEOPLASMS; PROLACTINOMA; TUMOR MARKERS, BIOLOGICAL;

EID: 33947733122     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.1.02339     Document Type: Review

References (108)

1. Ciccarelli A, Daly AF & Beckers A. The epidemiology of prolactinomas. Pituitary 2005 8 3-6.
2. Drange MR, Fram NR, Herman-Bonert V & Melmed S. Pituitary tumor registry:a novel clinical resource. Journal of Clinical Endocrinology and Metabolism 2000 85 168-174.
3. Ramot Y, Rapoport MJ, Hagag P & Wysenbeek AJ. A study of the clinical differences between women and men with hyperprolactinemia. Gynecological Endocrinology 1996 10 397-400.
4. Choudhury SD & Goswami A. Hyperprolactinemia and reproductive disorders - a profile from north east. Journal of the Association of Physicians of India 1995 43 617-618.
5. Batrinos ML, Panitsa-Faflia C, Tsiganou E & Liapi C. Incidence and characteristics of microprolactinomas (3-5 mm) in 4199 women assayed for prolactin. Hormone and Metabolic Research 1992 24 384-391.
6. Arafah BM & Nasrallah MP. Pituitary tumors: pathophysiology, clinical manifestations and management. Endocrine-Related Cancer 2001 8 287-305.
7. Colao A, Sarno AD, Cappabianca P, Briganti F, Pivonello R, Somma CD, Faggiano, A, Biondi B & Lombardi G. Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia. European Journal of Endocrinology 2003 148 325-331.
8. Delgrange E, Trouillas J, Maiter D, Donckier J & Tourniaire J. Sex-related difference in the growth of prolactinomas: a clinical and proliferation marker study. Journal of Clinical Endocrinology and Metabolism 1997 82 2102-2107.
9. Ozgen T, Oruckaptan HH, Ozcan OE & Acikgoz B. Prolactin secreting pituitary adenomas: analysis of 429 surgically treated patients, effect of adjuvant treatment modalities and review of the literature. Acta Neurochirurgica 1999 141 1287-1294.
10. Ohtakara K, Matsubara T, Kojima T, Taki W & Waga S. Cerebrospinal fluid rhinorrhea associated with untreated prolactinoma - case report. Neurologia Medico-chirurgica 2000 40 413-418.
11. Scarone P, Losa M, Mortini P & Giovanelli M. Obstructive hydrocephalus and intracranial hypertension caused by a giant macroprolactinoma. Prompt response to medical treatment. Journal of Neuro-oncology 2006 76 51-54.
12. Clayton RN. Sporadic pituitary tumours: from epidemiology to use of databases. Bailliere's Best Practice and Research. Clinical Endocrinology and Metabolism 1999 13 451-460.
13. Buurman H & Saeger W Subclinical adenomas in postmortem pituitaries: classification and correlations to clinical data. European Journal of Endocrinology 2006 154 753-758.
14. Schlechte J, Dolan K, Sherman B, Chapler F & Luciano A. The natural history of untreated hyperprolactinemia: a prospective analysis. Journal of Clinical Endocrinology and Metabolism 1989 68 412-418.
15. Weiss MH, Teal J, Gott P, Wycoff R, Yadley R, Apuzzo ML, Giannotta SL, Kletzky O & March C. Natural history of microprolactinomas: six-year follow-up. Neurosurgery 1983 12 180-183.
16. Turner HE & Wass JA. Are markers of proliferation valuable in the histological assessment of pituitary tumours? Pituitary 1999 1 147-151.
17. Pernicone PJ, Scheithauer BW, Sebo TJ, Kovacs KT, Horvath E, Young WF Jr, Lloyd RV, Davis DH, Guthrie BL & Schoene WC. Pituitary carcinoma: a clinicopathologic study of 15 cases. Cancer 1997 79 804-812.
18. Scheithauer BW, Kovacs KT, Laws ER Jr & Randall RV. Pathology of invasive pituitary tumors with special reference to functional classification. Journal of Neurosurgery 1986 65 733-744.
19. DeLellis RA, Lloyd RV, Heitz PU & Eng C Tumour of the pituitary gland. In World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Endocrine Organs. Ch 1, pp 10-47. Eds RA DeLellis, RV Lloyd, PU Heitz & C Eng, Lyon: IARC Press 2004.
20. Al-Shraim M & Asa SL. The 2004 World Health Organization classification of pituitary tumors: what is new? Acta Neuropathologica 2006 111 1-7.
21. Scheithauer BW, Gaffey TA, Lloyd RV, Sebo TJ, Kovacs KT, Horvath E, Yapicier O, Young WF Jr, Meyer FB, Kuroki T, Riehle DL & Laws ER Jr. Pathobiology of pituitary adenomas and carcinomas. Neurosurgery 2006 59 341.
22. Bevan JS, Webster J & Burke CW. Dopamine agonists and pituitary tumour shrinkage. Endocrine Reviews 1992 13 221-235.
23. Liuzzi A, Dallabonzana D, Oppizzi G, Verde GG, Cozzi R, Chiodini P & Luccarelli G. Low dose of dopamine agonists in the long-term treatment of macroprolactinomas. New England Journal of Medicine 1985 313 656-659.
24. Wass JA, Moult PJ, Thorner MO, Dacie JE, Charlesworth M, Jones AE & Besser GM. Reduction of pituitary-tumour size in patients with prolactinomas and acromegaly treated with bromocriptine with or without radiotherapy. Lancet 1979 2 66-69.
25. Fleseriu M, Lee M, Pineyro MM, Skugor M, Reddy SK, Siraj ES & Hamrahian AH. Giant invasive pituitary prolactinoma with falsely low serum prolactin: the significance of 'hook effect'. Journal of Neuro-oncology 2006 79 41-43.
26. Wu ZB, Yu CJ, Su PZ, Zhuge QC, Wu JS & Zheng WM. Bromocriptine treatment of invasive giant prolactinomas involving the cavernous sinus: results of a long-term follow up. Journal of Neurosurgery 2006 104 54-61.
27. Calle-Rodrigue RD, Giannini C, Scheithauer BW, Lloyd RV, Wollan PC, Kovacs KT, Stefaneanu L, Ebright AB, Abboud CF & Davis DH. Prolactinomas in male and female patients: a comparative clinicopathologic study. Mayo Clinic Proceedings 1998 73 1046-1052.
28. Ma W, Ikeda H & Yoshimoto T. Clinicopathologic study of 123 cases of prolactin-secreting pituitary adenomas with special reference to multihormone production and clonality of adenomas. Cancer 2002 95 166-258.
29. Cottier J-P, Destrieux C, Brunereau L, Bertrand P, Moreau L, Jan M & Herbreteau D. Cavernous sinus invasion by pituitary adenoma: MR imaging. Radiology 2000 215 463-469.
30. Molitch ME. Pharmacologic resistance in prolactinoma patients. Pituitary 2005 8 43-52.
31. Yildiz F, Zorlu F, Erbas T & Atahan L. Radiotherapy in the management of giant pituitary adenomas. Radiotherapy and Oncology 1999 52 233-237.
32. Di Sarno A, Landi ML, Marzullo P, Di Somma C, Pivonello R, Cerbone G, Lombardi G & Colao A. The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas. Clinical Endocrinology 2000 53 53-60.
33. Di Sarno A, Landi ML, Cappabianca P, Di Salle F, Rossi FW, Pivonello R, Di Somma C, Faggiano A, Lombardi G & Colao A. Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy. Journal of Clinical Endocrinology and Metabolism 2001 86 5256-5261.
34. Caccavelli L, Feron F, Morange I, Rouer E, Benarous R, Dewailly D, Jaquet P, Kordon C & Enjalbert A. Decreased expression of the two D2 dopamine receptor isoforms in bromocriptine-resistant prolactinomas. Neuroendocrinology 1994 60 314-322.
35. Thapar K, Yamada Y, Scheithauer B, Kovacs K & Stefaneanu L. Assessment of mitotic activity in pituitary adenomas and carcinomas. Endocrine Pathology 1996 7 215-221.
36. Thapar K, Kovacs K, Scheithauer BW, Stefaneanu L, Horvath E, Murray D & Laws ER Jr. Proliferative activity and invasiveness among pituitary adenomas and carcinomas: an analysis using the MIB-1 antibody. Neurosurgery 1996 38 99-106.
37. Hsu DW, Hakim F, Biller BMK, de la Monte S, Zervas NT, Klibanski A & Hadley-Whyte ET. Significance of proliferating cell nuclear antigen index in predicting pituitary adenoma recurrence. Journal of Neurosurgery 1993 78 753-761.
38. Atkin SL, Green VL, Hipkin LJ, Landolt AM, Foy PM, Jeffreys RV & White MC. A comparison of proliferation indices in human anterior pituitary adenomas using formalin fixed tissue and in vitro cell culture. Journal of Neurosurgery 1997 87 85-88.
39. Honegger J, Prettin C, Feuerhake F, Ptrick M, Schulte-Monting J & Reincke M. Expression of Ki-67 antigen in nonfunctioning pituitary adenomas: correlation with growth velocity and invasiveness. Journal of Neurosurgery 2003 99 674-679.
40. Sherr CJ. Mammalian G1 cyclins. Cell 1993 73 1059-1065.
41. Jordan S, Lidhar K, Korbonits M, Lowe DG & Grossman AB. Cyclin D and cyclin E expression in normal and adenomatous pituitary. European Journal of Endocrinology 2000 143 R1-R6.
42. Turner HE, Nagy ZS, Sullivan N, Esiri MM & Wass JAH. Expression analysis of cyclins in pituitary adenomas and the normal pituitary gland. Clinical Endocrinology 2000 53 337-344.
43. Pines J. Cyclins and cyclin-dependent kinases;theme and variations. Advances in Cancer Research 1995 66 181-212.
44. Betticher D, Thatcher N, Altermatt HJ, Hoban P, Ryder WD & Heighway J. Alternate splicing produces a novel cyclin D1 transcript. Oncogene 1995 11 1005-1011.
45. Matthias C, Branigan K, Jahnke V, Leder K, Haas J, Heighway J, Jones PW, Strange RC, Fryer AA & Hoban PR. Polymorphism in the cyclin D1 gene is associated with prognosis in patients with squamous cell carcinoma of the head and neck. Clinical Cancer Research 1998 4 2411-2418.
46. Simpson DJ, Fryer AA, Grossman AB, Wass JA, Pfeifer M, Kros JM, Clayton RN & Farrell WE. Cyclin D1 (CCND 1) genotype is associated with tumour grade in sporadic pituitary adenomas. Carcinogenesis 2001 22 1801-1807.
47. Spada A, Mantovani G & Lania A. Pathogenesis of prolactinomas. Pituitary 2005 8 7-15.
48. Fedele M, Battista S, Kenyon L, Baldassarre G, Fidanza V, Klein-Szanto AJ, Parlow AF, Visone R, Pierantom GM, Outwater E, Santoro M, Croce CM & Fusco A. Overexpression of the HMGA2 gene in transgenic mice leads to the onset of pituitary adenomas. Oncogene 2002 21 3190-3198.
49. Finelli P, Pierantoni GM, Giardino D, Losa M, Rodeschini O, Fedele M, Valtorta E, Mortim F, Croce CM, Larizza L & Fusco A. The High Mobility Group A2 gene is amplified and overexpressed in human prolactinomas. Cancer Research 2002 62 2398-2405.
50. Edelman GM. Cell adhesion molecules in the regulation of animal form and tissue pattern. Annual Review of Cell Biology 1986 2 81-116.
51. Williams A & Barclay AN. The immunoglobulin superfamily, domains for cell surface recognition. Annual Review of Immunology 1988 6 381-405.
52. Sadoul R, Hirn M, Deagostini-Bazin H, Rougon G & Goridis C. Adult and embryonic mouse neural cell adhesion molecules have different binding properties. Nature 1983 304 347-349.
53. Jin L, Hemperly JJ & Lloyd RV. Expression of neural cell adhesion molecule in normal and neoplastic human neuroendocrine tissues. American Journal of Pathology 1991 138 961-969.
54. Figarella-Branger DF, Durbec PL & Rougon GN. Differential spectrum of expression of neural cell adhesion molecule isoforms and L1 adhesion molecules on human neuroectodermal tumors. Cancer Research 1990 50 6364-6370.
55. Komminoth P, Roth J, Lackie PM, Bitter-Suermann D & Heitz PU. Polysialic acid of the neural cell adhesion molecule distinguishes small cell lung carcinoma from carcinoids. American Journal of Pathology 1991 139 297-304.
56. Daniel L, Trouillas J, Renaud W, Chevallier P, Gouvernet J, Rougon G & Figarella-Branger D. Polysialylated-neural cell adhesion molecule expression in rat pituitary transplantable tumors (spontaneous mammotropic transplantable tumor in Wistar-Furth rats) is related to growth rate and malignancy. Cancer Research 2000 60 80-85.
57. Trouillas J, Daniel L, Guigard MP, Tong S, Gouvernet J, Jouanneau E, Jan M, Perrin G, Fischer G, Tabarin A, Rougon G & Figarella-Branger D. Polysialylated neural cell adhesion molecules expressed in human pituitary tumors and related to extrasellar invasion. Journal of Neurosurgery 2003 98 1084-1093.
58. Vleminckx K, Vakaet L Jr, Mareel M, Fiers W & van Roy F. Genetic manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion suppressor role. Cell 1991 66 107-119.
59. Ozawa M, Baribault H & Kemler R. The cytoplasmic domain of the cell adhesion molecule uvomorulin associates with three independent proteins structurally related in different species. EMBO Journal 1989 8 1711-1717.
60. Gumbiner BM & McCrea PD. Catenins as mediators of the cytoplasmic functions of cadherins. Journal of Cell Science 1993 17 155-158.
61. Shibamoto S, Hayakawa M, Takeuchi K, Hori T, Miyazawa K, Kitamura N, Johnson KR, Wheelock MJ, Matsuyoshi N & Takeichi M. Association of p120, a tyrosine kinase substrate, with E-cadherin/catenin complexes. Journal of Cell Biology 1995 128 949-957.
62. Van Aken E, De Wever O, Correia da Rocha AS & Mareel M. Defective Ecadherin/catenin complexes in human cancer. Virchows Archiv 2001 439 725-751.
63. Qian ZR, Li CC, Yamasaki H, Mizusawa N, Yoshimoto K, Yamada S, Tashiro T, Horiguchi H, Wakatsuki S, Hirokawa M & Sano T. Role of E-cadherin, alpha-, beta-, and gamma-catenins, and p120 (cell adhesion molecules) in prolactinoma behavior. Modern Pathology 2002 15 1357-1365.
64. Kawamoto H, Mizoue T, Arita K, Tominaga A, Eguchi K & Kurisu K. Expression of epithelial cadherin and cavernous sinus invasion in human pituitary adenomas. Journal of Neuro-Oncology 1997 34 105-109.
65. Paez-Pereda M, Kuchenbauer F, Arzt E & Stalla GK. Regulation of pituitary hormones and cell proliferation by components of the extracellular matrix. Brazilian Journal of Medical and Biological Research 2005 38 1487-1494.
66. Kuchenbauer F, Theodoropoulou M, Hopfner U, Stalla J, Renner U, Tonn JC, Low MJ, Arzt E, Stalla GK & Paez-Pereda M. Laminin inhibits lactotroph proliferation and is reduced in early prolactinoma development. Molecular and Cellular Endocrinology 2003 207 13-20.
67. Murphy G & Docherty AJ. The matrix metalloproteinases and their inhibitors. American Journal of Respiratory Cell and Molecular Biology 1992 7 120-125.
68. Stetler-Stevenson WG, Liotta LA & Kleiner DE Jr. Extracellular matrix 6: role of matrix metalloproteinases in tumor invasion and metastasis. FASEB Journal 1993 7 1434-1441.
69. Sang QXA. Complex role of matrix metalloproteinases in angiogenesis. Cell Research 1998 8 171-177.
70. Knappe UJ, Hagel C, Lisboa BW, Wilczak W, Ludecke DK & Saeger W. Expression of serine proteases and metalloproteinases in human pituitary adenomas and anterior pituitary lobe tissue. Acta Neuropathologica 2003 106 471-478.
71. Turner HE, Nagy Z, Esiri MM, Harris AL & Wass JA. Role of matrix metalloproteinase 9 in pituitary tumor behavior. Journal of Clinical Endocrinology and Metabolism 2000 85 2931-2935.
72. Fan X & Childs GV Epidermal growth factor and transforming growth factor-alpha messenger ribonucleic acids and their receptors in the rat anterior pituitary: localization and regulation. Endocrinology 1995 136 2284-2293.
73. Chabot JG, Walker P & Pelletier G. Distribution of epidermal growth factor binding sites in the adult rat anterior pituitary gland. Peptides 1986 7 45-50.
74. Jaffrain-Rea ML, Petrangeli E, Lubrano C, Minniti G, Di Stefano D, Sciarra F, Frati L, Tamburrano G, Cantore G & Gulino A. Epidermal growth factor binding sites in human pituitary macroadenomas. Journal of Endocrinology 1998 158 425-433.
75. Folkman J. What is the evidence that tumors are angiogenesis dependent? Journal of the National Cancer Institute 1990 82 4-6.
76. Turner HE, Nagy Z, Gatter KC, Esiri MM, Harris AL & Wass JA. Angiogenesis in pituitary adenomas and the normal pituitary gland. Journal of Clinical Endocrinology and Metabolism 2000 85 1159-1162.
77. de la Torre NG, Turner HE & Wass JA. Angiogenesis in prolactinomas: regulation and relationship with tumour behaviour. Pituitary 2005 8 17-23.
78. Turner HE, Nagy Z, Gatter KC, Esiri MM, Harris AL & Wass JA. Angiogenesis in pituitary adenomas - relationship to endocrine function, treatment and outcome. Journal of Endocrinology 2000 165 475-481.
79. Turner HE, Nagy Z, Gatter KC, Esiri MM, Wass JA & Harris AL. Proliferation, bcl-2 expression and angiogenesis in pituitary adenomas:relationship to tumour behaviour. British Journal of Cancer 2000 82 1441-1445.
80. Spada A, Mantovani G & Lania A. Pathogenesis of prolactinomas. Pituitary 2005 8 7-15.
81. Barbacid M. Ras genes. Annual Review of Biochemistry 1987 56 779-827.
82. Karga HJ, Alexander JM, Hedley-Whyte ET, Klibanski A & Jameson JL. Ras mutations in human pituitary tumors. Journal of Clinical Endocrinology and Metabolism 1992 74 914-919.
83. Cai WY, Alexander JM, Hedley-Whyte ET, Scheithauer BW, Jameson JL, Zervas NT & Klibanski A. Ras mutations in human prolactinomas and pituitary carcinomas. Journal of Clinical Endocrinology and Metabolism 1994 78 89-93.
84. Jacks T, Fazeli A, Schmitt EM, Bronson RT, Goodell MA & Weinberg RA. Effects of an Rb mutation in the mouse. Nature 1992 359 295-300.
85. Nakayama K, Ishida N, Shirane M, Inomata A, Inoue T, Shishido N, Horii I, Loh DY & Nakayama K. Mice lacking p27(Kipl) display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell 1996 85 707-720.
86. Pei L, Melmed S, Scheithauer B, Kovacs K, Benedict WF & Prager D. Frequent loss of heterozygosity at the retinoblastoma susceptibility gene (RB) locus in aggressive pituitary tumors: evidence for a chromosome 13 tumor suppressor gene other than RB. Cancer Research 1995 55 1613-1616.
87. Bates AS, Farrell WE, Bicknell EJ, McNicol AM, Talbot AJ, Broome JC, Perrett CW, Thakker RV & Clayton RN. Allelic deletion in pituitary adenomas reflects aggressive biological activity and has potential value as a prognostic marker. Journal of Clinical Endocrinology and Metabolism 1997 82 818-824.
88. Herman V, Drazin NZ, Gonsky R & Melmed S. Molecular screening of pituitary adenomas for gene mutations and rearrangements. Journal of Clinical Endocrinology and Metabolism 1993 77 5-55.
89. Weil RJ, Vortmeyer AO, Huang S, Boni R, Lubensky IA, Pack S. Marx SJ, Zhuang Z & Oldfield EH. 11q13 allelic loss in pituitary tumors in patients with multiple endocrine neoplasia syndrome type 1. Clinical Cancer Research 1998 4 1673-1678.
90. Poncin J, Stevenaert A & Beckers A. Somatic MEN1 gene mutation does not contribute significantly to sporadic pituitary tumorigenesis. European Journal of Endocrinology 1999 140 573-576.
91. Wenbin C, Asai A, Teramoto A, Sanno N & Kirino T. Mutations of the MEN1 tumor suppressor gene in sporadic pituitary tumors. Cancer Letters 1999 142 43-47.
92. Verges B, Boureille F, Goudet P, Murat A, Beckers A, Sassolas G, Cougard P, Chambe B, Montvernay C & Calender A. Pituitary disease in MEN type 1 (MEN1): data from the France-Belgium MEN1 multicenter study. Journal of Clinical Endocrinology and Metabolism 2002 87 457-465.
93. Burgess JR, Shepherd JJ, Parameswaran V, Hoffman L & Greenaway TM. Prolactinomas in a large kindred with multiple endocrine neoplasia type 1:clinical features and inheritance pattern. Journal of Clinical Endocrinology and Metabolism 1996 81 1841-1845.
94. Carty SE, Helm AK, Amico JA, Clarke MR, Foley TP, Watson CG & Mulvihill JJ. The variable penetrance and spectrum of manifestations of multiple endocrine neoplasia type 1. Surgery 1998 124 1106-1113.
95. Sakamoto H, Mori M, Taira M, Yoshida T, Matsukawa S, Shimizu K, Sekiguchi M, Terada M & Sugimura T. Transforming gene from human stomach cancers and a noncancerous portion of stomach mucosa. PNAS 1986 83 3997-4001.
96. Gonsky R, Herman V, Melmed S & Fagin J. Transforming DNA sequences present in human prolactin-secreting pituitary tumors. Molecular Endocrinology 1991 5 1687-1695.
97. Shimon I, Hinton DR, Weiss MH & Melmed S. Prolactinomas express human heparin-binding secretory transforming gene (hst) protein product: marker of tumour invasiveness. Clinical Endocrinology 1998 48 23-29.
98. Prezant TR, Kadioglu P & Melmed S. An intronless homolog of human protooncogene hPTTG is expressed in pituitary tumors: evidence for hPTTG family. Journal of Clinical Endocrinology and Metabolism 1999 84 1149-1152.
99. Zhang X, Horwitz GA, Prezant TR, Valentini A, Nakashima M, Bronstein MD & Melmed S. Structure, expression, and function of human pituitary tumor-transforming gene (PTTG). Molecular Endocrinology 1999 13 156-166.
100. Zou H, McGarry TJ, Bernal T & Kirschner MW Identification of a vertebrate sister-chromatid separation inhibitor involved in transformation and tumorigenesis. Science 1999 285 418-422.
101. Heaney AP, Horwitz GA, Wang Z, Singson R & Melmed S. Early involvement of estrogen-induced pituitary tumor transforming gene and fibroblast growth factor expression in prolactinoma pathogenesis. Nature Medicine 1999 5 1317--1321.
102. Toffle RC, Webb SM, Tagatz GE, Taylor S, Nagel TC, Campbell B, Phipps W & Okagaki T. Pregnancy-induced changes in prolactinomas as assessed with computed tomography. Journal of Reproductive Medicine 1988 33 821-826.
103. Stefaneanu L, Kovacs K, Horvath E, Lloyd RV, Buchfelder M, Fahlbusch R & Smyth H. In situ hybridization study of estrogen receptor messenger ribonucleic acid in human adenohypophysial cells and pituitary adenomas. Journal of Clinical Endocrinology and Metabolism 1994 78 83-88.
104. Gillam MP, Molitch ME, Lombardi G & Colao A. Advances in the treatment of prolactinomas. Endocrine Reviews 2006 27 485-534.
105. Zhang X, Horwitz GA, Heaney AF, Nakashima M, Prezant TR, Bronstein MD & Melmed S. Pituitary tumor transforming gene (PTTG) expression in pituitary adenomas. Journal of Clinical Endocrinology and Metabolism 1999 84 761-767.
106. Pandey J, Bannout A & Wendell DL. The Edpm5 locus prevents the 'angiogenic switch' in an estrogen-induced rat pituitary tumor. Carcinogenesis 2004 25 1829-1838.
107. Kelly MA, Rubinstein M, Asa SL, Zhang G, Saez C, Bunzow JR, Allen RG, Hnasko R, Ben-Jonathan N, Grandy DK & Low MJ. Pituitary lactotroph hyperplasia and chronic hyperprolactinemia in dopamine D2 receptor-deficient mice. Neuron 1997 19 103-113.
108. Friedman E, Adams EF, Hoog A, Gejman PV, Carson E, Larsson C, De Marco L, Werner S, Fahlbusch R & Nordenskjold M. Normal structural doparnme type 2 receptor gone in prolactin-secreting and other pituitary tumors. Journal of Clinical Endocrinology and Metabolism 1994 78 568-574.